GlassScriptPhysician profile
Eddie L Irions
NPI 1285885988
$4,952.42
in general payments reported to CMS, 2019-2025
26 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $92.24 · 2021: $147 · 2022: $30.33 · 2023: $468 · 2024: $497 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,585.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $482.97 | 2019-2025 | Xifaxan, Trulance |
| Sandoz INC. | $179.16 | 2024-2025 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $158.46 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $155.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $147.16 | 2021 | |
| Ardelyx, INC. | $128.88 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $128.82 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $128.49 | 2025 | Iqirvo |
| Janssen Biotech, INC. | $121.83 | 2023-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $110.26 | 2019 | |
| Pfizer INC. | $99.90 | 2019-2024 | |
| Lilly USA, LLC | $85.05 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $82.22 | 2025 | Voquezna |
| Genzyme Corporation | $67.15 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $56.70 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $54.82 | 2025 | Zenpep |
| Qol Medical, LLC | $36.49 | 2024 | Sucraid |
| Celltrion USA INC. | $36.42 | 2025 | Vegzelma |
| Mirum Pharmaceuticals, INC. | $21.64 | 2025 | Livmarli |
| Daiichi Sankyo INC. | $16.01 | 2020 | |
| Boston Scientific Corporation | $15.78 | 2019 | |
| Merck Sharp & Dohme LLC | $14.99 | 2024 | Dificid |
| Evoke Pharma, INC. | $14.43 | 2024 | |
| Allergan, INC. | $12.52 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Irions listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.